Navigation Links
China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
Date:1/14/2008

NEW YORK and HAIKOU, China, Jan. 14 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (''China Pharma'') (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced that it has retained HC International, Inc. (HCI) to initiate a proactive and targeted investor relations campaign. Matthew Hayden and Alan Sheinwald of HCI, and their collective team, will be advising the Company in all facets of public financial communications.

HC International is a premier information resource to institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms and accredited individual investors. HCI will leverage its recognized investment community relationships to help capitalize on China Pharma's key assets while helping management to articulate its accomplishments to date and its future growth opportunities. Additionally, the firm will help to extend China Pharma's market development, investor awareness and shareholder communications.

China Pharma, through its subsidiary, Hainan Helpson Bio-pharmaceutical Co., Ltd, is a specialty pharmaceutical company that develops, manufactures and markets generic and brand pharmaceutical products for both western and traditional Chinese medicines in China. The Company focuses on therapeutics for CNS, cardiovascular, cerebrovascular, wound recovery, and infectious diseases. Its products are sold in more than 20 provinces, sovereignties, and autonomous regions through 16 sales offices and approximately 680 proxy agents in China. China Pharma generated revenues of $24.0 million and net income of $8.8 million in the first nine months of 2007, up 75.6% and 72.0%, respectively, from the same period of 2006.

"This is an exciting time for China Pharma Holdings, Inc. as we continue to expand our business,'' said Ms. Zhilin Li, CEO of China Pharma Holdings, Inc. "After careful review, we selected HC International to ensure that our shareholders and members of the investment community are properly informed of our growth strategy and competitive advantages, including our focus on addressing high mortality diseases in China which includes targeting specific patient populations. The team at HC International is well respected and has a proven track record of representing many successful China based, US listed companies, including those operating in the Pharmaceutical Industry. We are confident they will help us to improve our overall communication capabilities, which includes delivering our story and subsequent milestones to a larger, targeted base of investors.''

"China Pharma is a very profitable pharmaceutical manufacturer in China that is well positioned to capitalize on its core strengths to address a large emerging market opportunity," said Matthew Hayden, President of HC International. "Given its strong management team, research and development expertise, and diverse product pipeline of potential new drugs, China Pharma presents an attractive opportunity for investors by possessing the necessary assets to build shareholder value over the long term.''

About China Pharma Holdings, Inc., Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

About HC International, Inc.

HC International is a focused and dedicated organization that acts as a premier informational resource for institutional investors, hedge funds, buy and sell-side analysts, small to large brokerage firms and accredited investors. HC International helps their clients' companies package their corporate information in a clear, concise and consistent manner while facilitating introductions to the right investors at the most opportune time. For further information, please contact HC International directly, or visit the Company's Web site at http://www.hcinternational.net .

For more information, please contact:

China Pharma Holdings, Inc.

Sophia Yu

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

HC International, Inc.

Alan Sheinwald

Tel: +1-914-669-0222

Email: Alan.sheinwald@hcinternational.net


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation ... Physics and Astronomy, has been selected for membership in ARCS Alumni Hall of ... Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of the ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):